Sensei Biotherapeutics, Inc.
Buy Activity
Sell Activity
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $8.7M-13.3% | $10.0M-23.2% | $13.0M-26.9% | $17.8M |
| Marketable securities | $12.5M-60.1% | $31.3M-40.6% | $52.7M-40.9% | $89.3M |
| Prepaid expenses | $231K-51.3% | $474K-59.4% | $1.2M+3.5% | $1.1M |
| Other current assets | $92K-23.3% | $120K-63.1% | $325K-5.5% | $344K |
| Total current assets | $21.5M-48.7% | $41.9M-37.7% | $67.3M-38.1% | $108.6M |
| Right of use assets - operating leases, net | $1.3M-53.9% | $2.8M-35.2% | $4.3M-19.1% | $5.4M |
| Right of use assets - financing leases, net | $1K-99.4% | $163K-89.4% | $1.5M-33.5% | $2.3M |
| Property and equipment, net | $82K-80.3% | $417K-64.2% | $1.2M-43.1% | $2.0M |
| Other non-current assets | $18K-62.5% | $48K-44.2% | $86K+36.5% | $63K |
| Total assets | $22.9M-49.5% | $45.4M-39.0% | $74.4M-37.2% | $118.4M |
| Accounts payable and accrued liabilities | $1.5M+18.7% | $1.2M-26.3% | $1.7M-62.1% | $4.5M |
| Compensation and employee benefits liabilities | $1.3M-29.9% | $1.9M+24.6% | $1.5M-38.7% | $2.5M |
| Operating lease liabilities, current | $1.4M-13.6% | $1.6M+1.2% | $1.6M+25.3% | $1.3M |
| Financing lease liabilities, current | $80K-89.1% | $732K-16.1% | $872K-0.9% | $880K |
| Total current liabilities | $4.3M-22.0% | $5.4M-3.5% | $5.6M-37.8% | $9.1M |
| Operating lease liabilities, non-current | $59K-95.9% | $1.4M-52.4% | $3.0M-30.6% | $4.3M |
| Financing lease liabilities, non-current | $0-100.0% | $98K-87.2% | $768K-51.4% | $1.6M |
| Total liabilities | $4.3M-38.2% | $7.0M-26.4% | $9.5M-36.7% | $15.0M |
| Common stock, $0.0001 par value and 12,500,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,261,685 and 1,258,940 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0-100.0% | $3K+0.0% | $3K |
| Additional paid-in capital | $301.7M+0.4% | $300.5M+1.2% | $297.0M-1.7% | $302.2M |
| Accumulated deficit | -$283.1M-8.0% | -$262.1M-13.0% | -$231.9M-17.2% | -$197.8M |
| Accumulated other comprehensive loss | $1K+107.7% | -$13K+93.8% | -$209K+79.2% | -$1.0M |
| Total stockholders' equity | $18.6M-51.6% | $38.4M-40.8% | $64.9M-37.2% | $103.4M |
| Total liabilities and stockholders' equity | $22.9M-49.5% | $45.4M-39.0% | $74.4M-37.2% | $118.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | 2026-06-01 | Cambrian BioPharma Inc | 10% Owner | Sale | 25.0K | $20.02 | $501K | 130.1K | View | |
| 2026-04-07 | 2026-05-15 | MILLENNIUM MANAGEMENT LLC | 10% Owner | Sale | 8,151 | $31.01 | $253K | 134.0K | View | |
| 2026-04-07 | 2026-05-15 | MILLENNIUM MANAGEMENT LLC | 10% Owner | Purchase | 1,108 | $33.38 | $37K | 134.0K | View | |
| 2026-04-06 | 2026-05-15 | MILLENNIUM MANAGEMENT LLC | 10% Owner | Purchase | 1,104 | $31.02 | $34K | 141.0K | View | |
| 2026-04-06 | 2026-05-15 | MILLENNIUM MANAGEMENT LLC | 10% Owner | Sale | 1,259 | $31.06 | $39K | 141.0K | View |
Informational purposes only, not investment advice.